| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18802155 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 110 journal articles in the PubMed database | Email to a friend | | |
| Greenspan SL, Nelson JB, Trump DL, et al.
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. [Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural]
J Clin Oncol 2008 Sep 20; 26(27):4426-34.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Greenspan SL, Nelson JB, Trump DL, et al.
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. [Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural]
Ann Intern Med 2007 Mar 20; 146(6):416-24.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Michaelson MD, Kaufman DS, Lee H, et al.
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. [Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
J Clin Oncol 2007 Mar 20; 25(9):1038-42.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Greenspan SL, Coates P, Sereika SM, et al.
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. [Journal Article]
J Clin Endocrinol Metab 2005 Dec; 90(12):6410-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cohen A, Fleischer JB, Johnson MK, et al.
Prevention of bone loss after withdrawal of tamoxifen. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Endocr Pract 2008 Mar; 14(2):162-7.
Abstract | Full Citation | Find Related Articles | | Smith MR, Eastham J, Gleason DM, et al.
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Urol 2003 Jun; 169(6):2008-12.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kawahara T, Kobayashi T, Nishizawa K, et al.
Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer. [Journal Article]
Hinyokika Kiyo 2008 Apr; 54(4):261-6.
Abstract | Full Citation | | Ensrud KE, Barrett-Connor EL, Schwartz A, et al.
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Bone Miner Res 2004 Aug; 19(8):1259-69.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ryan CW, Huo D, Demers LM, et al.
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. [Journal Article]
J Urol 2006 Sep; 176(3):972-8; discussion 978.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
